205 related articles for article (PubMed ID: 24255083)
41. Methotrexate level discrepancy post-glucarpidase: A pediatric case series and review of literature.
Kibby D; Trinkman H
Pediatr Blood Cancer; 2024 Mar; 71(3):e30831. PubMed ID: 38149827
[TBL] [Abstract][Full Text] [Related]
42. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
[TBL] [Abstract][Full Text] [Related]
43. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.
Estève MA; Devictor-Pierre B; Galy G; André N; Coze C; Lacarelle B; Bernard JL; Monjanel-Mouterde S
Eur J Clin Pharmacol; 2007 Jan; 63(1):39-42. PubMed ID: 17115148
[No Abstract] [Full Text] [Related]
44. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Widemann BC
Pediatr Blood Cancer; 2016 Feb; 63(2):366. PubMed ID: 26488622
[No Abstract] [Full Text] [Related]
45. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
46. Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity.
Smith SW; Nelson LS
J Med Toxicol; 2008 Jun; 4(2):132-40. PubMed ID: 18570175
[No Abstract] [Full Text] [Related]
47. [Carboxypeptidase-G2 rescue of methotrexate intoxication].
Grill J; Amigo-Ferreiro ME; Schoepfer C; Bonnay M; Valteau-Couanet D; Hartmann O; Vassal G
Bull Cancer; 1998 Dec; 85(12):1066. PubMed ID: 9917559
[No Abstract] [Full Text] [Related]
48. Therapeutic Drug Monitoring of Methotrexate in Plasma Using Ultra High-Performance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry: Necessary After Administration of Glucarpidase in Methotrexate Intoxications.
Mulder MB; Huisman R; Engels FK; van der Sluis IM; Koch BCP
Ther Drug Monit; 2018 Aug; 40(4):383-385. PubMed ID: 29994985
[TBL] [Abstract][Full Text] [Related]
49. [Acute toxicity of high doses of methotrexate in treatment of ALL in children: a case study].
Periáñez-Párraga L; Pérez-Rodríguez O; do Pazo-Oubiña F; Crespí-Monjo M
Farm Hosp; 2009; 33(3):172-3. PubMed ID: 19712601
[No Abstract] [Full Text] [Related]
50. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
51. Production of "biobetter" variants of glucarpidase with enhanced enzyme activity.
Al-Qahtani AD; Bashraheel SS; Rashidi FB; O'Connor CD; Romero AR; Domling A; Goda SK
Biomed Pharmacother; 2019 Apr; 112():108725. PubMed ID: 30970523
[TBL] [Abstract][Full Text] [Related]
52. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR
Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903
[TBL] [Abstract][Full Text] [Related]
53. [Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure].
von Poblozki A; Dempke W; Schmoll HJ
Med Klin (Munich); 2000 Aug; 95(8):457-60. PubMed ID: 10985069
[TBL] [Abstract][Full Text] [Related]
54. Commentary.
Milone MC
Clin Chem; 2010 Dec; 56(12):1795-6. PubMed ID: 21119036
[No Abstract] [Full Text] [Related]
55. Nephrotoxicity due to intermediate-dose methotrexate without rescue in an obese adolescent with acute lymphoblastic leukemia.
Sauer M; Rydholm N; Piatkowski J; Lewis V; Steiner M
Pediatr Hematol Oncol; 2002 Mar; 19(2):135-40. PubMed ID: 11881788
[TBL] [Abstract][Full Text] [Related]
56. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.
Vilay AM; Mueller BA; Haines H; Alten JA; Askenazi DJ
Pharmacotherapy; 2010 Jan; 30(1):111. PubMed ID: 20030480
[TBL] [Abstract][Full Text] [Related]
57. Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Meyers PA
Pediatr Blood Cancer; 2016 Feb; 63(2):364. PubMed ID: 26488216
[No Abstract] [Full Text] [Related]
58. Commentary.
Fox E; Balis FM
Clin Chem; 2010 Dec; 56(12):1795. PubMed ID: 21119037
[No Abstract] [Full Text] [Related]
59. Risk factors for high-dose methotrexate-induced nephrotoxicity.
Kawaguchi S; Fujiwara SI; Murahashi R; Nakashima H; Matsuoka S; Ikeda T; Toda Y; Ito S; Ban T; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Kanda Y
Int J Hematol; 2021 Jul; 114(1):79-84. PubMed ID: 33743109
[TBL] [Abstract][Full Text] [Related]
60. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Scott JR; Crews KR
Pediatr Blood Cancer; 2016 Feb; 63(2):365. PubMed ID: 26488798
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
